LINEAGE CELL THERAPEUTICS INC (LCTX) competitors & alternatives
Health Care · NYSE American
LINEAGE CELL THERAPEUTICS INC (LCTX)'s top competitors and alternatives — its most similar public companies — include CENTURY THERAPEUTICS INC (IPSC), Vertex Pharmaceuticals (VRTX), CRISPR THERAPEUTICS AG (CRSP), PROKIDNEY CORP CLASS A (PROK), CABALETTA BIO INC (CABA), VOR BIOPHARMA INC (VOR), SANA BIOTECHNOLOGY INC (SANA), VERICEL CORP (VCEL), ARTIVA BIOTHERAPEUTICS INC (ARTV), KYVERNA THERAPEUTICS INC (KYTX), PROTARA THERAPEUTICS INC (TARA) and SURROZEN INC (SRZN). These are LINEAGE CELL THERAPEUTICS INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top LCTX competitors & alternatives
-
CENTURY THERAPEUTICS INCIPSCHealth Care
Century Therapeutics is an innovative biotechnology firm developing off-the-shelf, gene-edited iPSC-derived cell therapies to cure cancer and autoimmune…
$2.15 (as of 2026-07-22) · market cap $388M
-
Vertex PharmaceuticalsVRTXHealth Care
Vertex Pharmaceuticals develops transformative medicines for serious genetic diseases, with a dominant pipeline anchored in cystic fibrosis treatments and…
$472.57 (as of 2026-07-22) · market cap $121.4B
-
CRISPR THERAPEUTICS AGCRSPHealth Care
CRISPR Therapeutics develops gene-editing medicines using CRISPR/Cas9 technology, with the first approved CRISPR therapy (CASGEVY) for sickle cell disease and…
$47.24 (as of 2026-07-22) · market cap $4.6B
-
PROKIDNEY CORP CLASS APROKHealth Care
ProKidney is pioneering a first-in-class autologous kidney cell therapy to slow kidney function decline in advanced CKD and diabetes patients, currently in…
$1.53 (as of 2026-07-22) · market cap $462M
-
CABALETTA BIO INCCABAHealth Care
Cabaletta Bio is a clinical-stage biotechnology firm developing one-time, curative CAR T cell therapies aimed at resetting the immune system for patients with…
$2.75 (as of 2026-07-22) · market cap $449M
-
VOR BIOPHARMA INCVORHealth Care
Vor Biopharma is a clinical-stage biopharmaceutical company developing advanced cell therapy and gene therapy solutions for blood disorders and cancers.
$19.51 (as of 2026-07-22) · market cap $1.1B
-
SANA BIOTECHNOLOGY INCSANAHealth Care
Sana Biotechnology is developing ex vivo and in vivo engineered cell therapy platforms to transform the treatment of diseases like type 1 diabetes, oncology,…
$3.12 (as of 2026-07-22) · market cap $868M
-
VERICEL CORPVCELHealth Care
Vericel is a leader in advanced autologous cell therapies for sports medicine and severe burn care, with FDA-approved products MACI for cartilage repair and…
$44.56 (as of 2026-07-22) · market cap $2.4B
-
ARTIVA BIOTHERAPEUTICS INCARTVHealth Care
Artiva Biotherapeutics develops allogeneic natural killer cell immunotherapies for cancer, with its lead candidate AlloNK advancing through clinical trials.
$10.02 (as of 2026-07-22) · market cap $487M
-
KYVERNA THERAPEUTICS INCKYTXHealth Care
Kyverna is a clinical-stage immunology biotech developing novel investigational therapeutics with no approved products and complete dependence on successful…
$7.40 (as of 2026-07-22) · market cap $452M
-
PROTARA THERAPEUTICS INCTARAHealth Care
Clinical-stage biopharmaceutical company developing TARA-002, a cell therapy based on an established immunopotentiator, and IV Choline Chloride for oncology,…
$4.08 (as of 2026-07-22) · market cap $229M
-
SURROZEN INCSRZNHealth Care
Surrozen is a clinical-stage biotechnology company developing regenerative therapies that harness the body's Wnt signaling pathway to repair tissue damage.
$21.72 (as of 2026-07-22) · market cap $252M
Not quite? Describe exactly what you want →
Peers are LINEAGE CELL THERAPEUTICS INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: LINEAGE CELL THERAPEUTICS INC (LCTX).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.